Potential Co-benefits and trade-offs between improved soil management, climate change mitigation and agri-food productivity

Maximising resource-use efficiency, productivity and environmental sustainability are all fundamental requirements to raise global food production by ~70 per cent in order to feed a world population of ~9.7 billion people by 2050. Perhaps the most vital resource within our capacity to achieve this goal is our soil. Broadly, the fundamental question concerns whether or not satisfying this production demand will accelerate soil degradation, climate change, and the loss of soil carbon stocks. This paper builds upon the outputs of the UK Charity ‘Food & Farming Futures’ (chaired by Lord Curry of Kirkharle) virtual workshop held on 23 March 2021, entitled ‘Capturing the Potential of Soil’. The event focussed on the link between soil health, primarily soil organic carbon (SOC), and agricultural productivity. Supported with commentaries by Professor Pete Smith (University of Aberdeen and Science Director of the Scottish Climate Change Centre of Expertise) and Professor Steve McGrath (Head of Sustainable Agricultural Sciences at Rothamsted Research), specific focus will be given to the research challenges within the UK’s ability to improve soil health and functionality, the implementation priorities that must be held in order to improve soil management by 2050 and what the potential co-benefits could be. These co-benefits were scattered across environmental, economic, social and political issues, yet they may be summarised into six primary co-benefits: developing natural capital, climate change mitigation, carbon trading, improvements in crop yield, animal performance and human health (nutrition). Additionally, the main barriers to improved soil management practices are centred on knowledge exchange-regarding agri-environmental techniques—whilst the most impactful solutions rely on soil monitoring, reporting and verification

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Soil carbon determination for long‐term monitoring revisited using thermo‐gravimetric analysis

Abstract Soils and the vadose zone are the major terrestrial repository of carbon (C) in the form of soil organic matter (SOM), more resistant black carbon (BC), and inorganic carbonate. Differentiating between these pools is important for assessing vulnerability to degradation and changes in the C cycle affecting soil health and climate regulation. Major monitoring programs from field to continent are now being undertaken to track changes in soil carbon (SC). Inexpensive, robust measures that can differentiate small changes in the C pools in a single measurement are highly desirable for long‐term monitoring. In this study, we assess the accuracy and precision of thermo‐gravimetric analysis (TGA) using organic matter standards, clay minerals, and soils from a national data set. We investigate the use of TGA to routinely differentiate between C pools, something no single measurement has yet achieved. Based on the kinetic nature of thermal oxidation of SC combined with the different thermodynamic stabilities of the molecules, we designed a new method to quantify the inorganic and organic SC and further separate the organic biogeochemically active SOM (as loss on ignition, LOI) from the resistant BC in soils. We analyze the TGA spectrums of a national soil monitoring data set (n = 456) and measure total carbon (TC) using thermal oxidation and also demonstrate a TC/LOI relationship of 0.55 for soils ranging from mineral soils to peat for the United Kingdom consistent with previous monitoring campaigns

Second‐line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes

BACKGROUND: Though gemcitabine plus platinum chemotherapy is the established first line regimen for advanced biliary tract cancer (ABC), there is no standard second line therapy. We evaluated current practice and outcomes for second line chemotherapy in patients with ABC across three US academic medical centers. METHODS: Institutional registries were reviewed to identify patients who had received second line chemotherapy for ABC from 4/2010 to 3/2015, along with demographics, diagnosis and staging, treatment history, and clinical outcomes. Overall survival from initiation of second line chemotherapy (OS2) was estimated using Kaplan-Meier methods. RESULTS: We identified 198 patients with cholangiocarcinoma (intrahepatic, 61.1% and extrahepatic, 14.1%) and gallbladder carcinoma (24.8%); 52% received at least 3 lines of systemic chemotherapy. The median OS2 11 months (95% CI 8.8-13.1). Median OS2 for intrahepatic cholangiocarcinoma was 13.4 months (95% CI: 10.7-17.8), longer than extrahepatic or gallbladder with mOS2 of 6.8 months (95% CI: 5-10.5) and 9.4 months (95% CI: 7.2-12.3), respectively (p=0.018). The median time to second line treatment failure was 2.2 (95% CI: 1.8-2.7) months, similar across tumor locations (p=0.60). CONCLUSIONS: In this large cohort of ABC patients treated across three academic medical centers after failure of first line chemotherapy, the time to treatment failure on standard therapies was short, though median OS2 was longer than has been reported previously, and over half of patients received additional lines of treatment. This multicenter collaboration represents the largest cohort studied to date of second line chemotherapy in ABC and provides a contemporary benchmark for future clinical trials

Second‐line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes

BackgroundAlthough gemcitabine plus platinum chemotherapy is the established first-line regimen for advanced biliary cancer (ABC), there is no standard second-line therapy. This study evaluated current practice and outcomes for second-line chemotherapy in patients with ABC across 3 US academic medical centers.MethodsInstitutional registries were reviewed to identify patients who had received second-line chemotherapy for ABC from April 2010 to March 2015 along with their demographics, diagnoses and staging, treatment histories, and clinical outcomes. Overall survival from the initiation of second-line chemotherapy (OS2) was estimated with Kaplan-Meier methods.ResultsThis study identified 198 patients with cholangiocarcinoma (intrahepatic [61.1%] or extrahepatic [14.1%]) or gallbladder carcinoma (24.8%); 52% received at least 3 lines of systemic chemotherapy. The median OS2 was 11 months (95% confidence interval [CI], 8.8-13.1 months). The median OS2 for patients with intrahepatic cholangiocarcinoma was 13.4 months (95% CI, 10.7-17.8 months), which was longer than that for patients with extrahepatic cholangiocarcinoma (6.8 months; 95% CI, 5-10.6 months) or gallbladder carcinoma (9.4 months; 95% CI, 7.2-12.3 months; P = .018). The median time to second-line treatment failure was 2.2 months (95% CI, 1.8-2.7 months), and it was similar across tumor locations (P = .60).ConclusionsIn this large cohort of patients with ABC treated across 3 academic medical centers after the failure of first-line chemotherapy, the time to treatment failure on standard therapies was short, although the median OS2 was longer than has been reported previously, and more than half of the patients received additional lines of treatment. This multicenter collaboration represents the largest cohort studied to date of second-line chemotherapy for ABC and provides a contemporary benchmark for future clinical trials

Nitrogen deposition effects on ecosystem services and interactions with other pollutants and climate change

Ecosystem services are defined as the ecological and socio-economic value of goods and services provided by natural and semi-natural ecosystems. Ecosystem services are being impacted by many human induced stresses, one of them being nitrogen (N) deposition and its interactions with other pollutants and climate change. It is concluded that N directly or indirectly affects a wide range of provisioning, regulating, supporting and cultural ecosystem services, many of which are interrelated. When considering the effects of N on ecosystem services, it is important to distinguish between different types of ecosystems/species and the protection against N impacts should include other aspects related to N, in addition to biodiversity. The Working Group considered the following priorities of ecosystem services in relation to N: biodiversity; air quality/atmosphere; ecosystem changes; NO3 leaching; climate regulation and cultural issues. These are the services for which the best evidence is available in the literature. There is a conflicting interest between greenhouse gas ecosystem services and biodiversity protection; up to some point of increasing N inputs, net greenhouse gas uptake is improved, while biodiversity is already adversely affected

"Eu não preciso falar que eu sou branca, cara, eu sou Latina!" Ou a complexidade da identificação racial na ideologia de ativistas jovens (não)brancas "I do not have to say that I am white, man, I am Latina!" Or the complexity of racial identification in the ideology of (non)white, young, female activists

Neste artigo procuro explorar a complexidade do processo de formação da identidade racial de mulheres, jovens ativistas (não)brancas em São Paulo. Levando em conta a interação do indivíduo com o mundo social, distingue-se a identidade racial apropriada da atribuída e a identidade racial individual da coletiva. Isso requer atenção para o papel da posição social racial, com as subsequentes vantagens raciais, para os sentimentos da ativista neste processo e para a influência mútua da heterogeneidade de identidade racial, do deslocamento da identidade racial e, por conseguinte, do papel da formação de identidade como estratégia de ideologia e práxis ativista.<br>In this article, I explore the complexity of racial identity formation of (non)white, young, female activists in São Paulo. Taking into account the interaction of the individual with the social world, one must distinguish between appropriated and attributed racial identities, as well as individual and collective identities. This requires attention to the role of racial social position and its subsequent racial advantages, to the feelings of activists about this process, and to the mutual influence of the heterogeneity of racial identity, the displacement of racial identity and, consequently, the role of identity formation as a strategy of activist ideology and praxis